AI Article Synopsis
- Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are rare chronic liver diseases that can lead to severe liver damage if not treated.
- Ursodeoxycholic acid is the traditional first-line treatment for PBC, with new medications like obeticholic acid and fibrates as second-line options, while PSC currently has no approved treatments except for liver transplants.
- Recent advances include two new FDA-approved drugs for PBC and ongoing research into additional therapies for both PBC and PSC, showing promise for future treatments.
Article Abstract
Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are rare, and chronic cholestatic diseases that can progress to liver failure. The goals of treatment are to halt the progression of liver disease to cirrhosis and/or liver failure, and alleviate symptoms associated with these diseases. Ursodeoxycholic acid has historically been the first-line treatment of PBC, with obeticholic acid and fibrates used as second-line or adjunctive therapies. However, the treatment landscape is rapidly expanding. Recently, 2 new second-line agents gained US Food and Drug Administration approval for the treatment of PBC, and several other therapies remain under investigation with promising results. Although significant progress has been made in the development of therapies for PBC, there are no current approved treatments of PSC other than liver transplantation although several emerging therapies have shown encouraging results. This review outlines the current and upcoming treatments of PBC and PSC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.14309/ajg.0000000000003174 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!